HIV and AIDS

BD Biosciences solutions for HIV provides absolute and percentage results of CD4 T lymphocytes to stage progression of HIV/AIDS, to guide treatment decisions for HIV-infected persons, and to evaluate the effectiveness of therapy.

Our commitment to help prevent, diagnose, and treat HIV/AIDS goes beyond the application of technology. We actively collaborate across public and private sectors to create effective and sustainable programs to build healthcare capacity.

BD collaborates across the private and public sectors to create effective and sustainable programs that help build healthcare capacity.

Of the more than 35.3 million people worldwide infected with HIV, only about 11.7 million have access to treatment (2013)*. The WHO goal is to increase that number to 15 million by 2015. According to the WHO 2013 guidelines, close to 26 million people are eligible for antiretroviral therapy (ART). As diagnostics, therapies, and healthcare infrastructure become more accessible, estimating CD4 lymphocyte counts guides initiation of ART and becomes a critical link in monitoring HIV infection and disease progression.


BD Biosciences instruments and reagents are used in CD4 testing. The BD FACSCount™ system is used in developing areas of the world where easy-to-use systems are needed. The BD FACSCalibur™ system is used in high-volume labs in resource-limited settings, and the BD FACSCanto™ II system is used for HIV monitoring and other applications when more sophisticated technologies are required.


* Does not constitute medical or legal advice, including with respect to regulatory practices or industry standards, specifically 21 CFR Part 58 Good Laboratory Practice for Nonclinical Laboratory Studies.

* Fact sheet: World Health Organization – HIV/AIDS fact sheet (2013); UNAIDS Treatment 2015; Global Update on the health sector response to HIV, WHO Executive Summary - July 2014